CSL welcomes MSAC support for gene therapy but questions 'strict cost-neutrality framework'

November 11, 2025 Latest News BioPharma

This is a preview of subscriber content

Subscribe now to continue reading.

The company has welcomed the recommendation but questioned the proposed pricing model, as it suggests cost neutrality compared to factor replacement therapy over 10 years. …

Subscribe now to continue reading.

Latest Video

Pfizer clinches Metsera, reshaping the balance in global obesity therapy race
November 11, 2025 - Latest News
Vaxxas appoints global vaccine leader to board as needle-free patch moves toward market
November 10, 2025 - Australian Biotech
CSL welcomes MSAC support for gene therapy but questions 'strict cost-neutrality framework'
November 11, 2025 - Latest News
Professor Robyn Ward - 'AI won’t replace us, but it will redefine how we work'
November 11, 2025 - Latest News
'AI Must Be trusted, transparent, and integrated in the future of health technology assessment'
November 11, 2025 - Latest News

CSL welcomes MSAC support for gene therapy but questions 'strict cost-neutrality framework'

This is a preview of subscriber content

Latest Video

Most Read

Pfizer clinches Metsera, reshaping the balance in global obesity therapy race

Vaxxas appoints global vaccine leader to board as needle-free patch moves toward market

CSL welcomes MSAC support for gene therapy but questions 'strict cost-neutrality framework'

Professor Robyn Ward - 'AI won’t replace us, but it will redefine how we work'

'AI Must Be trusted, transparent, and integrated in the future of health technology assessment'

New Stories

Australians open to AI in healthcare, but prefer doctors to be in control

Every Government agency to appoint a 'Chief AI Officer' under national plan

New Zealand accelerates medicines reform with major regulatory changes

FDA moves to lift long-standing hormone therapy warnings in major shift for women’s health

Optometry Australia and Alcon launch scholarship fund to support First Nations eye health leaders

Radiopharm Theranostics advances Phase 1 trial of 177Lu-RAD204 in PD-L1 positive cancers

Arovella appoints former CSL Chief Scientific Officer Dr Andrew Nash to its Board

Sign In

CSL welcomes MSAC support for gene therapy but questions 'strict cost-neutrality framework'

This is a preview of subscriber content

Latest Video

Most Read

Pfizer clinches Metsera, reshaping the balance in global obesity therapy race

Vaxxas appoints global vaccine leader to board as needle-free patch moves toward market

CSL welcomes MSAC support for gene therapy but questions 'strict cost-neutrality framework'

Professor Robyn Ward - 'AI won’t replace us, but it will redefine how we work'

'AI Must Be trusted, transparent, and integrated in the future of health technology assessment'

Follow Us

New Stories

Australians open to AI in healthcare, but prefer doctors to be in control

Every Government agency to appoint a 'Chief AI Officer' under national plan

New Zealand accelerates medicines reform with major regulatory changes

FDA moves to lift long-standing hormone therapy warnings in major shift for women’s health

Optometry Australia and Alcon launch scholarship fund to support First Nations eye health leaders

Radiopharm Theranostics advances Phase 1 trial of 177Lu-RAD204 in PD-L1 positive cancers

Arovella appoints former CSL Chief Scientific Officer Dr Andrew Nash to its Board